Development, Validation and Application of Advanced Biomarkers in Cerebral Tumours

Dear Colleagues,

Over the past 20 years, the concept of the biomarker has become intrinsic to medical research. The identification of individual quantifiable features related to tumour biology, tumour behaviour, prognosis, and treatment response has been one of the largest areas of original research. Following the discovery of potentially novel biomarkers, extensive research is needed to confirm their potential validity, prove their reproducibility and optimal methodology for measurement, and then explore and confirm their potential biological meaning. Biomarkers may be based on chemical, genetic or biological features, and may be extracted from data such as liquid biopsy, genome and gene expression data, imaging data, mass spectroscopy, proteomics or metabolomics. Whatever the methodology for individual biomarkers, they must be robust, reproducible, and provide valuable information concerning tumour biology, behaviour, prognosis, treatment response or some other aspect of tumour behaviour.

This Special Issue invites submissions related to the discovery, validation and application of novel biomarkers for the study and clinical management of intra-cerebral tumours. We will accept papers addressing the discovery of potential biomarkers, validation studies of existing biomarkers, and studies providing clinical validation or evidence of application of relatively novel biomarkers.

Prof. Dr. Alan Jackson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.